STUDresearch · Peptide
Stamakort
Also known as
Stamakort peptide · stomach-mucosa bioregulator
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Oral
Organ bioregulators
Targeted in marketing to the stomach, but documented use is oral capsules; systemic absorption and organ-selective delivery are unestablished.
What people say
Stamakort is an oral 10 mg capsule product described as a low-molecular-weight peptide complex isolated from calf or pig gastric mucosa. Stomach targeting is a marketing and sponsor-origin research claim; intact oral exposure and independent replication remain unclear.
Doses people talk about
Product strength, capsule count and course duration describe that report and retail culture; they do not establish oral absorption, a standard dose or a self-treatment protocol.
How it may feel
A sparse inspected forum report found no discernible gut effect and no negative effects while Stamakort was taken with other compounds by someone without current gut symptoms. A sponsor-origin 30-day add-on report described symptom improvement, but it did not establish a day-by-day felt clock.
Sponsor-origin gastritis report10–20 mg orally three times daily, 10–15 minutes before meals, for 30 days
Thirty participants received one or two 10 mg capsules per administration alongside usual therapy; 17 controls received usual therapy alone, with no blinding or placebo described.
Half-life & effect duration
- Half-life in the body
- Oral peptide complexNo settled estimate
- Felt duration people report
- One combination accountNo identifiable effect or negative effects
Cycles people discuss
Retail and bioregulator material commonly describes 10–30-day oral courses with months between repeats. The located sponsor-origin gastritis report used 30 days; these calendars are not a validated universal cycle.
Timing
The sponsor-origin gastritis report scheduled one or two 10 mg oral capsules three times daily, 10–15 minutes before meals, for 30 days. Retail 10–30-day and seasonal-repeat language is product culture, not a measured parent-peptide or benefit clock.
Stacks
Multi-bioregulator combinations appear in community protocols, but no Stamakort-specific combination trial establishes synergy. A solo comparison is easier to interpret than a multi-product course, although neither establishes efficacy.
Watch for
Oral safety evidence remains sparse: The sponsor-origin 30-day add-on report states that no side effects were observed, but its small, short, unblinded design and absent independent replication cannot establish uncommon or long-term safety.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A human plasma elimination half-life for intact orally administered Stamakort peptide components was not established.
The sponsor-origin report identifies a heterogeneous low-molecular-weight gastric-mucosa peptide complex in 10 mg capsules but provides no analyte-specific oral absorption or concentration-time study.
A mixture lacks one defined parent analyte, intact oral bioavailability was not measured, and general peptide digestion or course schedules cannot supply a numerical half-life.
- Khavinson — Report on the results of clinical study of biologically active food additive Stamakort (opens in a new tab)Translated sponsor-origin report describes a 10 mg gastric-mucosa peptide-complex capsule, 30 participants receiving 1–2 capsules three times daily, 10–15 minutes before meals, for 30 days, and 17 usual-therapy controls.Commercial host and inventor-associated report; no journal citation, blinding, placebo, allocation details, attrition analysis, analyte-specific PK or independent replication were provided on the reviewed page.
- Bioregulator Peptides UK — Stamakort: Benefits, Dosage and Evidence Reviewed (opens in a new tab)Commercial secondary review identifies Stamakort as an oral capsule product, explicitly says it is not injectable, distinguishes vendor course conventions from dose finding, and notes that intact oral survival and pharmacokinetics have not been established.Secondary web review rather than a primary study; commercial context and its literature search cannot prove that no inaccessible evidence exists.
Felt duration people report
No reproducible Stamakort-specific subjective onset or duration was established.
One forum author taking Stamakort with Ophthalamin and Semax while having no active gut symptoms could not identify an effect and reported no negative effects; the 30-day sponsor-origin report did not provide a day-by-day onset analysis.
A single confounded symptom-free self-report and an unblinded sponsor-origin add-on report cannot establish causality, prevalence, onset or persistence.
- Rapamycin Longevity News — Peptides / Bioregulators experience thread (opens in a new tab)One author reported taking imported oral Stamakort with Ophthalamin and Semax, having no current gut problems, being unable to tell whether Stamakort had an effect and noticing no negative effects at that point.Single unblinded self-report with concurrent compounds, no active baseline symptoms, no stated Stamakort amount or follow-up outcome, and unverified product identity.
- Khavinson — Report on the results of clinical study of biologically active food additive Stamakort (opens in a new tab)Translated sponsor-origin report describes a 10 mg gastric-mucosa peptide-complex capsule, 30 participants receiving 1–2 capsules three times daily, 10–15 minutes before meals, for 30 days, and 17 usual-therapy controls.Commercial host and inventor-associated report; no journal citation, blinding, placebo, allocation details, attrition analysis, analyte-specific PK or independent replication were provided on the reviewed page.
What people say
- stomach / GI mucosa narrative: Community and regional literature frame benefits around stomach / GI mucosa function and “normalization” language. forum
- What is thinner: Large modern multi-center RCTs are often absent for the specific peptide brand story. forum
- Organ-target lore: Stamakort is sold in Khavinson-style catalogs for a specific organ/system story rather than a systemic “GH peptide” narrative. forum
- Course culture: Users often describe multi-day to multi-week capsule courses, then breaks — more “seasonal tune-up” than daily forever. forum
- Subtlety claims: Benefits, when claimed, are usually mild (comfort, “support,” recovery feel) and hard to separate from sleep/diet. anecdote
Doses people talk about
- Duration talk: commonly 10–30 day courses, sometimes repeated 2–3×/year in vendor literature. forum
- Honesty: these are marketing-course numbers, not robust Western RCTs for every named product. forum
- Sponsor-origin clinical report: Stamakort contained 10 mg per capsule; 30 participants with chronic gastritis received 1–2 oral capsules three times daily, 10–15 minutes before meals, for 30 days in addition to usual therapy, while 17 controls received usual therapy alone. Blinding and placebo control were not reported. trial
- Framing: Khavinson-style organ peptide / bioregulator retail culture — not FDA-approved disease therapy. forum
How it may feel
- Inspected user report: One author taking oral Stamakort with Ophthalamin and Semax said they had no current gut symptoms, could not tell whether Stamakort was doing anything and had noticed no negative effects so far. The concurrent products and symptom-free baseline prevent attribution. forumanecdote
- Courses: Often 10–20 day courses repeated a few times per year in bioregulator culture. forum
- Day 1: Most people notice logistics (route, sting, GI) more than a “miracle” effect from Stamakort. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: First honest checkpoint in self-logs. forum
Cycles people discuss
- Course culture: Short on, long off, repeat seasonally is the common pattern. forum
- Common pattern: Many self-protocols use weeks-on / weeks-off rather than indefinite daily use — cost and caution drive this more than hard science. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Human product PK: No formulation-specific parent-peptide plasma half-life or intact oral bioavailability measurement was located. Vendor course timing and the general expectation that peptides are digested do not supply an elimination value. forum
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- PK honesty: Stamakort bioregulator products rarely publish rigorous human PK packages in English literature. forum
More on what it is
- What it is: Stamakort — short bioregulatory peptide discussed for stomach / GI mucosa support in cytomedine/Khavinson-style catalogs. Khavinson-style / peptide bioregulator culture: short cytomedine peptides with organ-targeting marketing; human RCT base is often thin compared with marketing. forum
- Evidence honesty: Much of the English-web discussion is secondary summaries and vendor literature; treat claims cautiously. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Stamakort, not proof it works for you. forum
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Multi-bioregulator stacks: Often combined by organ system in protocols. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Generally mild claims: Vendor literature often claims good tolerability — independent long-term data limited. forum
- Allergy / unknown impurities: Gray-market risk. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
- Oral safety evidence remains sparse: The sponsor-origin 30-day add-on report states that no side effects were observed, but its small, short, unblinded design and absent independent replication cannot establish uncommon or long-term safety. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.